Top

Archives of Orthopaedic and Trauma Surgery

Published in:

21-10-2021 | Morbus Osgood-Schlatter | Arthroscopy and Sports Medicine

Hyperosmolar dextrose injection for Osgood–Schlatter disease: a double-blind, randomized controlled trial

Authors: Zhe Wu, Xiaoxian Tu, Zhiyuan Tu

Published in: Archives of Orthopaedic and Trauma Surgery | Issue 9/2022

Abstract

Objective

Osgood–Schlatter disease (OSD) is one of the common causes of long-term knee pain, leading to functional limitations, long-term deformity of the tubercle interfering with kneeling, and impaired peer-important sport participation. Nonetheless, patient management continues to rely on the usual conservative methods. This study examined the use of hyperosmolar dextrose injection in patients with OSD.

Methods

We conducted a randomized, double-blind clinical trial involving 70 patients with OSD. One group received a hyperosmolar dextrose injection (12.5%), while the other received a saline injection. The injections were conducted under ultrasound guidance. The Victorian Institute of Sport Assessment (VISA) score was used to assess each patient's pain and sport level.

Results

The dextrose group outperformed the saline group in improvement in the VISA-Patella (VISA-P) score from baseline to 3 months (27.1 ± 6.5 vs. 1.4 ± 2.6; mean difference 25.4 (22.4 to 28.3); p < .0001), 6 months (31.7 ± 7.9 vs. 25.2 ± 7.8; mean difference 6.2 (3.2 to 9.4); p < .0001), and 12 months (34 ± 9.0 vs. 28.2 ± 7.5; mean difference 5.5 (1.9 to 9.1); p = .0026). The changes in both groups were clinically important, suggesting that both therapies were active treatments. The dextrose group improved too rapidly for spontaneous improvement to explain much of this change.

Conclusion

After three injections, at the 6-month and 12-month follow-up visits, the VISA-P scores of the two groups were significantly improved; the dextrose group score was better than the saline group score, and there were significant differences between the two groups.

Rathleff MS, Roos EM, Olesen JL, Rasmussen S (2013) High prevalence of daily and multi-site pain–a cross-sectional population-based study among 3000 Danish adolescents. BMC Pediatr 13:191. https://doi.org/10.1186/1471-2431-13-191 CrossRefPubMedPubMedCentral

Mølgaard C, Rathleff MS, Simonsen O (2011) Patellofemoral pain syndrome and its association with hip, ankle, and foot function in 16- to 18-year-old high school students: a single-blind case-control study. J Am Podiatr Med Assoc 101(3):215–222. https://doi.org/10.7547/1010215 CrossRefPubMed

Osgood RB (1993) Lesions of the tibial tubercle occurring during adolescence. 1903. Clin Orthop Relat Res 286:4–9 CrossRef

de Lucena GL, dos Santos GC, Guerra RO (2011) Prevalence and associated factors of Osgood-Schlatter syndrome in a population-based sample of Brazilian adolescents. Am J Sports Med 39(2):415–420. https://doi.org/10.1177/0363546510383835 CrossRefPubMed

Md R, D V, (2003) Disability levels of college-aged men with a history of Osgood-Schlatter disease. J Strength Cond Res 17(4):659–663

Topol GA, Podesta LA, Reeves KD, Raya MF, Fullerton BD, Yeh HW (2011) Hyperosmolar dextrose injection for recalcitrant Osgood-Schlatter disease. Pediatrics 128(5):e1121-1128. https://doi.org/10.1542/peds.2010-1931 CrossRefPubMed

Hernandez-Sanchez S, Hidalgo MD, Gomez A (2014) Responsiveness of the VISA-P scale for patellar tendinopathy in athletes. Br J Sports Med 48(6):453–457. https://doi.org/10.1136/bjsports-2012-091163 CrossRefPubMed

Rabago D, Reeves KD, Topol GA, Podesta LA, Cheng AL, Fullerton BD (2020) Infrapatellar bursal injection with dextrose and saline are both effective treatments for Osgood-Schlatter disease. Letter to editor for: No superiority of dextrose injections over placebo injections for Osgood-Schlatter disease: a prospective randomized doubleblind study. https://doi.org/10.1007/s00402-019-03297-2.ArchOrthopTraumaSurg140(4):591-592.10.1007/s00402-020-03355-0 CrossRef

Nakase J, Oshima T, Takata Y, Shimozaki K, Asai K, Tsuchiya H (2019) No superiority of dextrose injections over placebo injections for Osgood-Schlatter disease: a prospective randomized double-blind study. Arch Orthop Trauma Surg. https://doi.org/10.1007/s00402-019-03297-2 CrossRefPubMed

10.

Guldhammer C, Rathleff MS, Jensen HP, Holden S (2019) Long-term prognosis and impact of Osgood-Schlatter disease 4 years after diagnosis: a retrospective study. Orthop J Sports Med 7(10):2325967119878136. https://doi.org/10.1177/2325967119878136 CrossRefPubMedPubMedCentral

11.

Circi E, Atalay Y, Beyzadeoglu T (2017) Treatment of Osgood-Schlatter disease: review of the literature. Musculoskelet Surg 101(3):195–200. https://doi.org/10.1007/s12306-017-0479-7 CrossRefPubMed

12.

Itoh G, Ishii H, Kato H, Nagano Y, Hayashi H, Funasaki H (2018) Risk assessment of the onset of Osgood-Schlatter disease using kinetic analysis of various motions in sports. PLoS ONE 13(1):e0190503. https://doi.org/10.1371/journal.pone.0190503 CrossRefPubMedPubMedCentral

13.

Watanabe H, Fujii M, Yoshimoto M, Abe H, Toda N, Higashiyama R, Takahira N (2018) Pathogenic factors associated with Osgood-Schlatter disease in adolescent male soccer players: a prospective cohort study. Orthop J Sports Med 6(8):2325967118792192. https://doi.org/10.1177/2325967118792192 CrossRefPubMedPubMedCentral

14.

Omodaka T, Ohsawa T, Tajika T, Shiozawa H, Hashimoto S, Ohmae H, Shitara H, Ichinose T, Sasaki T, Hamano N, Takagishi K, Chikuda H (2019) Relationship between lower limb tightness and practice time among adolescent baseball players with symptomatic Osgood-Schlatter disease. Orthop J Sports Med 7(5):2325967119847978. https://doi.org/10.1177/2325967119847978 CrossRefPubMedPubMedCentral

15.

Launay F (2015) Sports-related overuse injuries in children. Orthop Traumatol Surg Res 101(1 Suppl):S139-147. https://doi.org/10.1016/j.otsr.2014.06.030 CrossRefPubMed

16.

Kerssemakers SP, Fotiadou AN, de Jonge MC, Karantanas AH, Maas M (2009) Sport injuries in the paediatric and adolescent patient: a growing problem. Pediatr Radiol 39(5):471–484. https://doi.org/10.1007/s00247-009-1191-z CrossRefPubMed

17.

Arendt EA (2017) Editorial commentary: tibial tubercle prominence after Osgood-Schlatter disease: what causes pain? Arthroscopy 33(8):1558–1559. https://doi.org/10.1016/j.arthro.2017.04.001 CrossRefPubMed

18.

Pagenstert G, Wurm M, Gehmert S, Egloff C (2017) Reduction osteotomy of the prominent tibial tubercle after Osgood-Schlatter disease. Arthroscopy 33(8):1551–1557. https://doi.org/10.1016/j.arthro.2017.02.012 CrossRefPubMed

19.

Lui TH (2016) Endoscopic management of Osgood-Schlatter disease. Arthrosc Tech 5(1):e121-125. https://doi.org/10.1016/j.eats.2015.10.023 CrossRefPubMedPubMedCentral

20.

El-Husseini TF, Abdelgawad AA (2010) Results of surgical treatment of unresolved Osgood-Schlatter disease in adults. J Knee Surg 23(2):103–107. https://doi.org/10.1055/s-0030-1267474 CrossRefPubMed

21.

Hakala RV (2005) Prolotherapy (proliferation therapy) in the treatment of TMD. Cranio 23(4):283–288. https://doi.org/10.1179/crn.2005.040 CrossRefPubMed

22.

Hauser R, Hauser M, Baird N (2011) Evidence-based use of dextrose prolotherapy for musculoskeletal pain: A scientific literature review. J Prolotherapy 3(4):765–789

23.

Distel LM, Best TM (2011) Prolotherapy: a clinical review of its role in treating chronic musculoskeletal pain. Pm&R 3:S78–S81. https://doi.org/10.1016/j.pmrj.2011.04.003 CrossRef

24.

Rabago D, Slattengren A, Zgierska A (2010) Prolotherapy in primary care practice. Prim Care 37(1):65–80. https://doi.org/10.1016/j.pop.2009.09.013 CrossRefPubMedPubMedCentral

25.

Maxwell NJ, Ryan MB, Taunton JE, Gillies JH, Wong AD (2007) Sonographically guided intratendinous injection of hyperosmolar dextrose to treat chronic tendinosis of the Achilles tendon: a pilot study. AJR Am J Roentgenol 189(4):W215-220. https://doi.org/10.2214/AJR.06.1158 CrossRefPubMed

26.

Chan O, O’Dowd D, Padhiar N, Morrissey D, King J, Jalan R, Maffulli N, Crisp T (2008) High volume image guided injections in chronic Achilles tendinopathy. Disabil Rehabil 30(20–22):1697–1708. https://doi.org/10.1080/09638280701788225 CrossRefPubMed

Title: Hyperosmolar dextrose injection for Osgood–Schlatter disease: a double-blind, randomized controlled trial
Authors: Zhe Wu
Xiaoxian Tu
Zhiyuan Tu
Publication date: 21-10-2021
Publisher: Springer Berlin Heidelberg
Keyword: Morbus Osgood-Schlatter
Published in: Archives of Orthopaedic and Trauma Surgery / Issue 9/2022
Print ISSN: 0936-8051
Electronic ISSN: 1434-3916
DOI: https://doi.org/10.1007/s00402-021-04223-1

Keynote Webinar | Spotlight on Diet and Diabetes

Springer Medicine

Hyperosmolar dextrose injection for Osgood–Schlatter disease: a double-blind, randomized controlled trial

Abstract

Objective

Methods

Results

Conclusion

Keynote Webinar | Spotlight on Diet and Diabetes

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2022

Reduction of olecranon fractures with no or minimal dorsal cortex comminution based on the contour of the posterior ulnar cortex: does it restore the greater sigmoid notch?

Did implementation of three ligament tenodesis improve patient outcome after chronic scapholunate instability? A retrospective study

The accuracy of patient-reported weight prior to total joint arthroplasty and arthroscopy of the lower extremity

The Olympia anatomic polished cemented stem is associated with a high survivorship, excellent hip-specific functional outcome, and high satisfaction levels: follow-up of 239 consecutive patients beyond 15 years

Analysis of perioperative outcomes in hip resection arthroplasty

Patient-reported outcomes at 1 and 2 years after total hip and knee arthroplasty: what is the minimum required follow-up?